English
Français
Español
Deutsch
Italiano
Português
Nederlands
Polski
Română
Svenska
Dansk
Suomi
Čeština
Ελληνικά
Magyar
SlovenčinaData temporarily unavailable
Unable to load analysis for « - » for now. Try again in a few moments.
Investlytic score: 1/5 criteria met.
- ❌ Price trend failed
- ❌ Growth failed
- ✅ Debt passed
- ❌ P/E failed
- ❌ Correction failed
Price trend
Overall trend (8 years): insufficient progression (less than x1.5).
Price change 2020 → 2021: -13.02%
Price change 2021 → 2022: 6.17%
Price change 2022 → 2023: 475.14%
Price change 2023 → 2024: -10.33%
Price change 2024 → 2025: -75.66%
Price change 2025 → 2026: -12.97%
Price change 2026 (year to date): -4.02%
Financial growth
Revenue CAGR (6 years): N/A
Earnings CAGR (6 years): N/A
Growth status: insufficient data or negative trend.
Debt
Debt-to-equity ratio: 0.25
Debt/equity < 0.5 (maximum threshold).
P/E (Price/Earnings)
P/E ratio: -2.95
P/E > 25.0 (maximum threshold).
Correction (6 months)
Current correction: 48.24% from the high over 6 months.
Excessive correction (> 20.0%).
Criteria of the Investlytic model
- / 5Free with the Investlytic logo. Paste this line into your page: options.
<script src="https://investlytic.co/encart.js" data-symbole="MLTX" data-lang="en"></script>Price trend
Price & trend
Interactive chart →💰 Dividend
Dividend ranking →⚖️ Comparison with the market
All stocks →| Stock | P/E | Dette/FP | Revenue growth | Rating |
|---|---|---|---|---|
| MoonLake Immunotherapeutics | – | 0.25 | – | 🔒 |
| DocMorris AG | – | 0.71 | +5.7 % | – |
| Vetoquinol S.A. | 16.2 | 0.03 | +4.2 % | – |
| Pharming Group N.V. | 38.2 | 0.42 | +50.1 % | – |
| BioGaia AB (publ) | 31.2 | 0.01 | +13.3 % | ★ 4/5 |
Data from the Investlytic screener. The rating of the stock being viewed is reserved for members.
Detailed analysis · Price trend
-
Revenues & profits
Revenue and net income
Financial indicators
Annual financial statements
| Fiscal year | Revenue | Net income | Net margin | EPS | Revenue growth |
|---|
Accounts and financial health
Balance sheet and cash flow published by MoonLake Immunotherapeutics over the last fiscal years, strength scores and valuation by discounted cash flow (DCF).
| Fiscal year | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Cash and investments | 8.0 m | 72.1 m | 511 m | 448 m | 394 m |
| Total Debt | 15.0 m | 282,580 | 3.7 m | 2.8 m | 75.7 m |
| Net Debt | 7.0 m | -39.2 m | -447 m | -178 m | -259 m |
| Equity | -11.6 m | 48.9 m | 496 m | 447 m | 304 m |
| Total assets | 9.7 m | 76.8 m | 527 m | 478 m | 424 m |
| Operating cash flow | -35.2 m | -55.9 m | -42.8 m | -117 m | -196 m |
| Investments (capex) | 50,710 | 16,009 | 284,000 | 519,520 | 35,000 |
| Free cash-flow | -35.2 m | -55.9 m | -43.1 m | -117 m | -196 m |
| Share buybacks | 6,202 | 0 | 0 | 50 | 0 |
| Dividends paid | 0 | 0 | 0 | 0 | 0 |
Amounts in USD, currency of the published accounts.
Trailing 12-month ratios
Altman Z: default risk estimated from the balance sheet and earnings. Piotroski: 9 tests on profitability, debt and efficiency. DCF: estimated value from discounted future cash flows, a model and not a forecast. Source: annual accounts published by the company, data as of 09/11/2026.
Analyst consensus and forecasts
What the financial analysts covering MoonLake Immunotherapeutics publish: ratings, price targets and earnings forecasts.
Breakdown of ratings
Price targets: published for companies listed in the United States only.
Track record against expectations: reported EPS above consensus 4 times over the last 12 releases.
Source: ratings and forecasts published by analysts, collected on 07/11/2026. An analyst rating or target is not a guarantee.
Who owns the stock
Free float, institutional investors, large funds, executives and elected officials: declared positions in MoonLake Immunotherapeutics.
Large funds tracked
| Fund | Shares | Value (USD) | Weight in the fund | Change | Quarter |
|---|---|---|---|---|---|
| Citadel Advisors | 3.9 m | 76.8 m | 0.0 % | +198.1 % | 2026Q2 |
| D. E. Shaw & Co | 3.4 m | 65.5 m | 0.0 % | +40.8 % | 2026Q2 |
| Two Sigma Investments | 1.7 m | 33.4 m | 0.0 % | +52.8 % | 2026Q2 |
| JPMorgan Chase | 1.4 m | 27.6 m | 0.0 % | +27.4 % | 2026Q2 |
| Point72 Asset Management | 1.2 m | 22.6 m | 0.0 % | -15.3 % | 2026Q2 |
| BlackRock | 1.1 m | 21.3 m | 0.0 % | +7.1 % | 2026Q2 |
| T. Rowe Price | 1.0 m | 20.3 m | 0.0 % | -19.6 % | 2026Q2 |
| Bank of America | 751,897 | 14.6 m | 0.0 % | +3.7 % | 2026Q2 |
Latest insider transactions
| Date | Person | Side | Amount |
|---|---|---|---|
| 27/07/2026 | Reich Kristian | sale | 22,000 USD |
| 22/07/2026 | Reich Kristian | sale | 48,960 USD |
| 21/07/2026 | Reich Kristian | sale | 1.0 m USD |
| 20/07/2026 | Reich Kristian | sale | 877,933 USD |
| 15/07/2026 | Reich Kristian | sale | 322,261 USD |
| 10/07/2026 | Santos Da Silva Jorge | sale | 1.4 m USD |
Sources: 13F filings (quarter shown), executives' Form 4 filings and US Congress members' disclosures, collected on 08/11/2026. Detailed disclosure obligations mainly apply to companies listed in the United States.
PEA and practical information
Rule applied: the French PEA accepts shares of companies headquartered in the European Union or the European Economic Area and subject to corporate income tax; ADRs and tax-exempt property companies (SIIC) are excluded. The institution holding the PEA confirms eligibility.
Frequently asked questions about MoonLake Immunotherapeutics
What is the MoonLake Immunotherapeutics share price?
Latest recorded price: 11.53 USD on 06/11/2026, for a market cap of 981 m USD.
What do analysts say about MoonLake Immunotherapeutics?
Out of 19 analysts: 15 buy or strong buy, 2 hold, 2 sell or strong sell.
Is MoonLake Immunotherapeutics stock eligible for the French PEA?
No: the company is headquartered outside the European Union and the European Economic Area (ISIN KY61559X1045).
How many employees does MoonLake Immunotherapeutics have?
100 full-time employees according to the latest published profile.
Who runs MoonLake Immunotherapeutics?
Jorge Santos da Silva is the company's chief executive.
Which large funds own MoonLake Immunotherapeutics?
As of 2026Q2, among the large funds tracked: Citadel Advisors, D. E. Shaw & Co, Two Sigma Investments, JPMorgan Chase, Point72 Asset Management.